Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.50 |
| ▸ | MAPT | P10636 | 4/20 | 0.50 |
| ▸ | MEN1 | O00255 | 3/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | NAMPT | P43490 | 1/20 | 0.47 |
| ▸ | BRD4 | O60885 | 1/20 | 0.46 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.46 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.45 |
| ▸ | NPFFR1 | Q9GZQ6 | 1/20 | 0.44 |
| ▸ | NPFFR2 | Q9Y5X5 | 1/20 | 0.44 |
| ▸ | PARP1 | P09874 | 1/20 | 0.43 |
| ▸ | DRD4 | P21917 | 2/20 | 0.42 |
| ▸ | DRD2 | P14416 | 1/20 | 0.42 |
| ▸ | SUCNR1 | Q9BXA5 | 1/20 | 0.42 |
| ▸ | DRD3 | P35462 | 1/20 | 0.42 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL971814 | 0.85 | HTR6 (0.44) | KDM4EMAPTMEN1KMT2ALMNA | |
| SCHEMBL12801757 | 0.83 | LNPEP (0.48) | KDM4EMAPTMEN1KMT2ALMNA | |
| SCHEMBL27679071 | 0.82 | NAMPT (0.49) | KDM4EMAPTMEN1KMT2ALMNA | |
| SCHEMBL29995938 | 0.82 | NPFFR1 (0.49) | KMT2ANAMPTNPFFR1NPFFR2DRD2 | |
| SCHEMBL5577789 | 0.80 | CHRM3 (0.51) | KDM4EMAPTMEN1KMT2ALMNA | |
| SCHEMBL5577729 | 0.79 | CHRM3 (0.60) | KDM4EMAPTMEN1KMT2ALMNA | |
| SCHEMBL18664426 | 0.78 | HDAC1 (0.60) | BRD4CREBBPHDAC1 | |
| SCHEMBL5577708 | 0.77 | CHRM3 (0.54) | KDM4EMAPTMEN1KMT2ALMNA | |
| SCHEMBL5577732 | 0.77 | CHRM3 (0.65) | MAPTMEN1KMT2ALMNADRD2 | |
| SCHEMBL5577393 | 0.77 | CHRM3 (0.55) | KDM4EMAPTMEN1KMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130225825-A1 | PROCESS FOR THE PREPARATION OF TRYPTASE INHIBITORS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2013-08-29 | — | — | US | claimed |
| JP-4851440-B2 | — | — | 2012-01-11 | — | — | JP | claimed |
| EP-1723140-B1 | PROCESS FOR THE PREPARATION OF TRYPTASE INHIBITORS | AVENTIS PHARMA INC (US) | 2009-11-04 | — | — | EP | claimed |
| CN-101429194-A | Process for the preparation of tryptase inhibitors | AVENTIS PHARMA INC (US) | 2009-05-13 | — | — | CN | claimed |
| US-20070197597-A1 | Process for the preparation of tryptase inhibitors | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-08-23 | — | — | US | claimed |
| CN-1950362-A | Preparation method of tryptase inhibitor | AVENTIS PHARMA INC (US) | 2007-04-18 | — | — | CN | claimed |
| EP-1723140-A1 | PROCESS FOR THE PREPARATION OF TRYPTASE INHIBITORS | Aventis Pharmaceuticals Inc. (US) | 2006-11-22 | — | — | EP | claimed |
| WO-2005095385-A1 | PROCESS FOR THE PREPARATION OF TRYPTASE INHIBITORS | AVENTIS PHARMACEUTICALS INC. (US) | 2005-10-13 | — | — | WO | claimed |
| US-20130225825-A1 | PROCESS FOR THE PREPARATION OF TRYPTASE INHIBITORS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2013-08-29 | — | — | US | disclosed |
| CN-101429194-B | Process for the preparation of tryptase inhibitors | AVENTIS PHARMACEUTICALS, INC. (US) | 2011-12-14 | — | — | CN | disclosed |
| US-20110015400-A1 | PROCESS FOR THE PREPARATION OF TRYPTASE INHIBITORS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2011-01-20 | — | — | US | disclosed |
| US-20110015400-A1 | PROCESS FOR THE PREPARATION OF TRYPTASE INHIBITORS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2011-01-20 | — | — | US | disclosed |
| CN-1950362-B | Preparation method of tryptase inhibitor | AVENTIS PHARMA INC | 2010-08-04 | — | — | CN | disclosed |
| EP-1723140-B1 | PROCESS FOR THE PREPARATION OF TRYPTASE INHIBITORS | AVENTIS PHARMA INC (US) | 2009-11-04 | — | — | EP | disclosed |
| US-20070197597-A1 | Process for the preparation of tryptase inhibitors | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-08-23 | — | — | US | disclosed |
| US-20070197597-A1 | Process for the preparation of tryptase inhibitors | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-08-23 | — | — | US | disclosed |
| CN-1950362-A | Preparation method of tryptase inhibitor | AVENTIS PHARMA INC (US) | 2007-04-18 | — | — | CN | disclosed |
| EP-1723140-A1 | PROCESS FOR THE PREPARATION OF TRYPTASE INHIBITORS | Aventis Pharmaceuticals Inc. (US) | 2006-11-22 | — | — | EP | disclosed |
| WO-2005095385-A1 | PROCESS FOR THE PREPARATION OF TRYPTASE INHIBITORS | AVENTIS PHARMACEUTICALS INC. (US) | 2005-10-13 | — | — | WO | disclosed |
| EP-1571150-A1 | Process for the preparation of tryptase inhibitors | Aventis Pharma Deutschland GmbH (DE) | 2005-09-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130225825-A1 | PROCESS FOR THE PREPARATION OF TRYPTASE INHIBITORS | CMA1, TPSAB1, TPSB2 | KDM4E 1980/4885MAPT 2268/4885MEN1 222/4885 |
| US-20110015400-A1 | PROCESS FOR THE PREPARATION OF TRYPTASE INHIBITORS | CMA1, TPSAB1, TPSB2 | KDM4E 1980/4885MAPT 2268/4885MEN1 222/4885 |
| US-20070197597-A1 | Process for the preparation of tryptase inhibitors | CMA1, TPSAB1, TPSB2 | KDM4E 1980/4885MAPT 2268/4885MEN1 222/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.